Condition: Pregnant, Healthy Females · Healthy Male Newborns · Sponsor: Hadassah Medical Organization
Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation. The major goal of the project is to develop human iPS cells from existing lines of fibroblasts that were originally donated as clinical grade feeders for the development of clinical grade hESCs. The clinical grade feeders were developed from aborted fetuses, foreskin and umbilical cord.
This description comes directly from the study's public registry record.
Benjamin E Reubinoff, MD PhD · 011-972-2-6774569 · benjaminr@ekmd.huji.ac.il
Shelly E. Tannenbaum, MSQA · 011-972-2-572-2000 · stannenbaum@hadassah.org.il
Always discuss trial participation with your own doctor first.
| Hadassah Ein Kerem | Jerusalem, Israel, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00801372